




**Supplementary Figure 1. Survival assay of DPSCs after CSC and nicotine treatment.** DPSCs were seeded at 20,000 cells per well and treated with; **A**: 25 µg/ml to 500 µg/ml of CSC, or **B**: 100 nM to 10 mM nicotine. Test was conducted in triplicates. **B** and **D**: quantification of the colonies (10 pictures per treatment concentration were analyzed using Image J), ANOVA two-way test, \* $p < 0.05$ ,  $n = 3$  experiments.





**Supplementary Figure 2.** Cytokines array of cell culture medium of DPSCs treated with 100  $\mu$ g/ml of CSC or 1 mM nicotine for 48 hours; **A** and **C**: The C5 membranes; Dots quantification (3 pictures per treatment concentration were analyzed using Image J), \* $p < 0.05$ . **B** and **D**: the Volcano plots, the x-axis shows fold change for each cytokine, The y-axis shows the variable importance of change ( $-\log_{10}(p \text{ value})$ ). Cut-offs of fold change over 0.5 and under -0.5, and  $-\log_{10}(p \text{ value}) > 1$ , were used and are illustrated by dotted lines.  $n=3$  experiments.

### CSC exposure



### Nicotine exposure



**Supplementary Figure 3.** AMES test showing the revertants after CSC and nicotine exposures. TA102 was exposed to different concentrations of CSC (25, 50, and 100, 250, and 500  $\mu\text{g/ml}$ ), or nicotine (100 nM, 1,  $\mu\text{M}$ , 10  $\mu\text{M}$ , 100  $\mu\text{M}$ , and 1 mM), in the absence and the presence of S9 activation.

**Table S1:** List of qPCR primers.

Gene	Forward primers	Reverse primers
B-actin	AGAGCTACGAGCTGCCTGAC	AGCACTGTGTTGGCGTACAG
IL-6	ACTCACCTCTTCAGAACGAATTG	CCATCTTTGGAAGGTTTCAGGTTG
IL-10	GACTTTAAGGGTTACCTGGGTTG	TCACATGCGCCTTGATGTCTG
TGF- $\beta$ 1	TACCTGAACCCGTGTTGCTCTC	GTTGCTGAGGTATCGCCAGGAA
TNF- $\alpha$	CCCCAGGGACCTCTCTCTAATC	GGTTTGCTACAACATGGGCTACA

© 2023 Tahrani Hardin L. et al.